[EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS [FR] COMPOSÉS TÉTRAHYDROISOQUINOLINES SUBSTITUÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
The preparation of imides via the palladium-catalyzed coupling reaction of organostannanes is described. The palladium-catalyzed coupling reaction of aryl-, heteroaryl-, and alkenyl(tributyl)stannanes with methyl N-[methoxy(methylthio)methylene]carbamate in the presence of Cu(I) thiophene-2-carboxylate (CuTC) affords imino ethers, which are converted to the corresponding imides in high yield through acid hydrolysis.
Novel Quinidine-Derived Organocatalysts for the Asymmetric Substitutions of O-Boc-Protected Morita-Baylis-Hillman Adducts
作者:Cheng-Kui Pei、Xiu-Chun Zhang、Min Shi
DOI:10.1002/ejoc.201100501
日期:2011.8
A series of novelquinidine-derivedorganocatalysts was synthesized and utilized for the asymmetricsubstitution of O-Boc-protectedMorita–Baylis–Hillmanadducts with various carbamates and tosylcarbamates, affording the corresponding products in good to high yields (up to 91 % yield) with moderate to high ee values (up to 96 % ee) under mild conditions.
SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:US20150315200A1
公开(公告)日:2015-11-05
The present invention provides compounds of Formula (I):
or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US10000466B2
公开(公告)日:2018-06-19
The present invention provides compounds of Formula (I):
or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US10906886B2
公开(公告)日:2021-02-02
The present invention provides compounds of Formula (I):
or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa andor plasma kallikrein which may be used as medicaments.